Formulation and development of ternary hybrid matrix tablets of diltiazem hydrochloride

Polyethylene oxide (PEO) has been extensively used as an extended-release excipient in matrix tablets due to its extraordinarily safe, stable, soluble, swellable and erodible properties. The present study aimed to develop once-daily sustained-release tablets using PEO for a highly water-soluble drug, diltiazem hydrochloride (DH), the clinical application of which is limited because of its short half-life in vivo. However, the prophase study demonstrated that the use of PEO alone could only retard the drug release to 8 h. Thus, we proposed its combined use with chitosan/sodium alginate and formulated ternary matrix tablets by direct compression, in the hope of further extending the release of DH. 

More